Trial Profile

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Felzartamab in Adults With IgA Nephropathy (PREVAIL)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Felzartamab (Primary) ; Buclizine/codeine-phosphate/paracetamol; Cetirizine/pseudoephedrine; Desloratadine; Famotidine; Fexofenadine; Lidocaine/methylprednisolone-acetate; Loratadine/pseudoephedrine
Indications IgA nephropathy
Focus Registrational; Therapeutic Use
Acronyms PREVAIL
Sponsors Biogen

Most Recent Events

21 May 2025 Status changed from not yet recruiting to recruiting.
20 Apr 2025 Status changed from planning to not yet recruiting.
11 Mar 2025 According to a Biogen media release, the company plans to initiate this trial in 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com